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Insulin secretionRecently published ﬁndings indicate that a knockout (KO) of soluble adenylyl cyclase (sAC, also known as AC-10)
gene expression in mice leads to defective glucoregulation that is characterized by reduced pancreatic insulin
secretion and reduced intraperitoneal glucose tolerance. Summarized here are current concepts regarding the
molecular basis for this phenotype, with special emphasis on the potential role of sAC as a determinant of
glucose-stimulated insulin secretion. Highlighted is new evidence that in pancreatic beta cells, oxidative glucose
metabolism stimulates mitochondrial CO2 production that in turn generates bicarbonate ion (HCO3
−). Since
HCO3− binds to and directly stimulates the activity of sAC, we propose that glucose-stimulated cAMP production
in beta cells is mediated not simply by transmembrane adenylyl cyclases (TMACs), but also by sAC. Based on
evidence that sAC is expressed in mitochondria, there exists the possibility that beta-cell glucose metabolism is
linked to mitochondrial cAMP production with consequent facilitation of oxidative phosphorylation. Since sAC
is also expressed in the cytoplasm, sAC catalyzed cAMP production may activate cAMP sensors such as PKA
and Epac2 to control ion channel function, intracellular Ca2+ handling, and Ca2+-dependent exocytosis. Thus,
we propose that the existence of sAC in beta cells provides a new and unexpected explanation for previously
reported actions of glucose metabolism to stimulate cAMP production. It seems possible that alterations of sAC
activity might be of importance when evaluating new strategies for the treatment of type 2 diabetes (T2DM),
or when evaluating why glucose metabolism fails to stimulate insulin secretion in patients diagnosed with
T2DM. This article is part of a Special Issue entitled: The role of soluble adenylyl cyclase in health and disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic beta cells secrete insulin in response to the increase of
blood glucose concentration that occurs after a meal [1]. Released insu-
lin acts at insulin receptors on the liver, fat, and muscle to promote the
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9841; fax: +1 315 464 1566.release of glucose into the circulation [2]. As levels of blood glucose
drop in response to insulin, this glucose-stimulated insulin secretion
(GSIS) is terminated so that circulating levels of insulin will return to
levels that are characteristic of the fasting state. When glucose fails to
stimulate insulin secretion, or when tissues with insulin receptors be-
come resistant to insulin, there can exist chronic hyperglycemia, as is
the case for individuals with type 2 diabetes mellitus (T2DM) [3].
Since a loss of GSIS can occur prior to the development of insulin resis-
tance in T2DM [4], there is at the present time great interest to under-
stand the molecular defects of GSIS that occur in the context of T2DM.
2. Pancreatic beta-cell stimulus-secretion coupling
When considering how glucose stimulates insulin secretion from
pancreatic beta cells, attention has focused on the “triggering” and “am-
pliﬁcation”mechanisms of beta-cell stimulus-secretion coupling (Fig. 1)
[5,6]. These two interdependent mechanisms of GSIS require beta-cell
glucose uptake that is mediated by a facilitative glucose transporter
(Glut1 for humans, Glut2 for rodents) [7,8]. However, the rate-limiting
step in glucose sensing is governed by glucokinase (GK) [9], a type
IV hexokinase that catalyzes the conversion of glucose to glucose-
6-phosphate (G6P) [10]. Oxidative glycolytic and mitochondrial
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Fig. 1. Triggering and ampliﬁcation pathways of GSIS. Pictured aremetabolic, ionic, and GPCR signaling pathways in a pancreatic beta-cell that mediate stimulatory actions of glucose and
glucagon-like peptide-1 (GLP-1) on insulin secretion. A readily releasable pool (RRP) of secretory granules is positioned immediately beneath the plasma membrane, whereas a reserve
pool (RP) of secretory granules is located deeper in the cytoplasm behind the cortical actin barrier (wavy line). The triggering pathway of GSIS links glucosemetabolism to depolarization-
induced Ca2+ inﬂux that triggers exocytosis of the RRP and RP. The ampliﬁcation pathway allowsmetabolic coupling factors to increase the efﬁciency of Ca2+ as a stimulus for exocytosis.
These actions of glucose are reinforced by GLP-1 acting at its GPCR to stimulate cAMP production with consequent activation of the cAMP sensors PKA and Epac2. Abbreviations: Kv, KCa,
voltage and Ca2+ dependent K+ channels; ΔVm, depolarization; PLCε, phospholipase C-epsilon.
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concentration ratio [11], and this key metabolic signal is directly
responsible for the closure of ATP-sensitive K+ channels (K-ATP),
depolarization, and Ca2+ inﬂux through voltage-dependent Ca2+
channels (VDCCs) [11].
Glucose-stimulated Ca2+ inﬂux through VDCCs constitutes a
“triggering” mechanism for the Ca2+-dependent exocytosis of
dense core secretory granules containing insulin (Fig. 1). More spe-
ciﬁcally, this triggering mechanism targets two distinct pools of se-
cretory granules that undergo Ca2+-dependent fusion with the
plasma membrane. These pools are a readily releasable pool (RRP)
and a reserve pool (RP) of secretory granules. The RRP and RP are dis-
tinguishable because exocytosis of the RRP is not constrained by a cy-
toskeletal cortical actin barrier, whereas exocytosis of the RP can
only occur after glucose-induced remodeling of the cortical actin
barrier [12,13]. Therefore, the RRP of secretory granules located at
or near the plasma membrane undergoes exocytosis quickly in
order to generate an immediate 1st phase of GSIS, whereas the RP
of secretory granules located deeper within the cytoplasm un-
dergoes exocytosis with a delay in order to generate a 2nd phase of
GSIS. Importantly, neither 1st nor 2nd phase GSIS can occur in the
absence of the Ca2+ signal that triggers exocytosis.
The “ampliﬁcation” mechanism of GSIS allows glucose metabolism
to increase the efﬁciency with which Ca2+ triggers exocytosis of secre-
tory granules located in the RRP and the RP (Fig. 1) [5,6]. Although glu-
cose metabolism promotes remodeling of the cortical actin barrier to
enhance secretory granule transit to the plasma membrane [12,13],
this remodeling may not explain how glucose metabolically ampliﬁes
insulin secretion [14–16]. Instead, glycolytic and/or mitochondrial me-
tabolites may be of primary importance [5,6]. As discussed below, the
second messenger adenosine-3′,5′-cyclic monophosphate (cAMP) is
another potential coupling factor linking glucose metabolism to ampli-
ﬁcation. It is generated in response to glucose metabolism, and itssynthesis is catalyzed by transmembrane adenylyl cyclases (TMACs)
and a soluble adenylyl cyclase (sAC) expressed in beta cells.
When considering the relative importance of “triggering” and
“ampliﬁcation” to the control of insulin secretion by cAMP, there
is evidence that in healthy beta cells, the ampliﬁcation mechanism
predominates. Thus, in healthy beta cells, glucose metabolism is
capable of generating the cytosolic Ca2+ signal that triggers exocy-
tosis. Under such conditions, cAMP ampliﬁes soluble NSF attach-
ment protein receptor (SNARE) complex-mediated actions of
Ca2+ to trigger the release of a relatively small number of secretory
granules located within the RRP [17]. Simultaneously, cAMP am-
pliﬁes the Ca2+-dependent exocytosis of a much larger pool of se-
cretory granules located in the RP [17]. These amplifying actions of
cAMP are detectable using methods of live-cell imaging in which it
is demonstrated that cAMP enhances the translocation of so-called
“restless newcomer” secretory granules from the cytoplasm to the
plasma membrane [18]. Restless newcomer secretory granules un-
dergo immediate fusion with the plasma membrane, and their exo-
cytosis is a major factor that underlies the ability of cAMP to
potentiate 1st and 2nd phase GSIS.
A different scenario existswhen one considers how cAMP stimulates
insulin secretion in patients with T2DM. In certain forms of this disor-
der, beta-cell glucose sensing is defective, possibly as a consequence of
altered glycolytic and/or mitochondrial metabolism [19,20]. Under
such conditions, glucosemetabolism fails to produce the increase of cy-
tosolic ATP/ADP concentration ratio that normally leads to K-ATP chan-
nel closure and depolarization-induced Ca2+ inﬂux that triggers insulin
exocytosis (Fig. 1). Remarkably, beta-cell glucose sensing is restored
after the administration of glucagon-like peptide-1 (GLP-1), a cAMP-
elevating agent that facilitates glucose-dependent ATP production,
while also raising the [Ca2+]i and potentiating GSIS [21,22]. For GLP-1,
Holz et al. deﬁne this restoration of glucose sensing as the induction of
beta-cell “glucose competence” [23–26].
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GSIS can be evaluated in vivo using a protocol in which glucose is ad-
ministered by intravenous infusion. When the glucose concentration is
stepped from a low to a high level, the 1st and 2nd phase kinetic compo-
nents of GSIS are measurable in healthy individuals, whereas there is a
characteristic loss of 1st and 2nd phase GSIS in T2DM [4]. Oneway to ex-
plain this loss of GSIS is that in T2DM there are reduced numbers of beta
cells [27]. Alternatively, there might be a molecular defect of exocytosis
that prevents GSIS [28,29]. Differentiating between these two possibili-
ties is not possible in vivo, but the results of post-mortem investigations
indicate that in T2DM, the loss of GSIS is not explained simply by a de-
crease in the total number of beta-cells in the islets [4]. Thus, when con-
sidering a molecular defect of GSIS as a potential contributing factor to
T2DM, it is surprising that the process of exocytosis involving the fusion
of secretory granules with the plasma membrane is reported not to be
disturbed in beta cells from donors with T2DM [30]. Such ﬁndings sug-
gest that in certain forms of T2DM, beta-cell stimulus-secretion coupling
is disrupted at an early step of glucose sensing [31]. For example, there
might be a defective coupling of glucose metabolism to K-ATP channel
closure and Ca2+ inﬂux that triggers exocytosis. If so, it is understandable
that T2DM patients can be treated with sulfonylureas (e.g., tolbutamide)
that directly inhibit K-ATP channels, orwith GLP-1 receptor agonists that
stimulate cAMP production in order to restore glucose sensing and K-
ATP channel closure. In this regard, there is great interest concerning
the identiﬁcation of beta-cell cAMP-elevating agents thatwill restore de-
fective GSIS, while also lowering levels of blood glucose in patients with
T2DM [34–38]. Ideally, these cAMP-elevating agents will not stimulate
excessive insulin secretion, and will not induce hypoglycemia, as can
be the case for sulfonylureas [32,33].
4. sAC is a bicarbonate-stimulated adenylyl cyclase potentially
important to GSIS
Here we advance the hypothesis that soluble adenylyl cyclase (sAC)
might constitute a newmolecular target for pharmacological interventionGLP-1
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A; SUR1, sulfonylurea receptor-1 subunit of K-ATP channels.in the treatment of T2DM.More speciﬁcally,wepropose that in T2DM, the
coupling of glucose metabolism to cAMP production is diminished, and
that activators of sAC will restore levels of cAMP so that defective GSIS
is repaired. Our hypothesis is based on the ﬁnding that sAC is a HCO3−
and Ca2+ stimulated adenylyl cyclase that also serves as a physiological
ATP sensor [39–46]. Our hypothesis is also consistentwith the established
fact that the oxidative metabolism of glucose generates CO2 and ATP
while also promoting an increase of [Ca2+]i in beta cells [47]. In our
model (Fig. 2), CO2 generated by glucose metabolism will be converted
by carbonic anhydrase (CA) to carbonic acid (H2CO3) that will dissociate
at physiological pH to generate HCO3−. Bicarbonate ion generated in this
mannerwill stimulate sAC to generate cAMP that in turn potentiates GSIS.
What evidence is there in support of this hypothesis? One ﬁnding of
potential signiﬁcance is that GSIS is reduced when rat islets are equili-
brated in saline to which no HCO3− is added [48,49]. This experimental
ﬁnding obtained in the 1970s is understandable since the balance of
CA-catalyzed HCO3− production is inﬂuenced by HCO3− transporters
that are responsive to intracellular and extracellular HCO3−. Potentially,
live-cell imaging techniques using cAMP biosensors such as Epac1-
camps can be employed in order to determine if sAC-catalyzed cAMP
production is sensitive to alterations of extracellular HCO3− concentra-
tion. In this regard, it might be possible to generate recombinant fusion
proteins of sAC and Epac1-camps so that levels of cAMP can be moni-
tored directly at the site of sAC-catalyzed cAMP production.
It is interesting to note that the CA inhibitor acetazolamide
suppresses GSIS from rat islets [50,51]. Potentially, this action of acet-
azolamide is a consequence of its ability to block HCO3− production
that normally couples sAC activation to the stimulation of insulin secre-
tion (Fig. 2). Alternatively, acetazolamidemight act non-speciﬁcally as a
Ca2+ channel blocker to suppress Ca2+ inﬂux that triggers insulin secre-
tion. In fact, acetazolamide is reported to reduce glucose-stimulated
Ca2+ inﬂux in rat islets [51]. Unfortunately, the interpretation of these
ﬁndings is complicated by the lack of electrophysiological data with
which to evaluate potential Ca2+ channel blocking actions of acetazol-
amide. Still, it should be noted that prior patch clamp studies demon-
strate an ability of cAMP to facilitate glucose-dependent Ca2+ inﬂux inap1
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inhibits Ca2+ inﬂuxby interferingwith sAC-catalyzed cAMPproduction.
Appropriate electrophysiological studies are needed to test whether
beta-cell Ca2+ channel activity is directly or indirectly inhibited by
acetazolamide.
Since beta cells express mitochondrial carbonic anhydrase V (CA-V)
[50], and since sAC activity in mitochondria facilitates oxidative phos-
phorylation in some cell types [56–58], it could be that sAC elevates
levels of cAMP in beta-cell mitochondria, thereby allowing oxidative
glucose metabolism to more efﬁciently stimulate insulin secretion
(Fig. 2). This concept is consistent with the established importance of
mitochondrial metabolism to GSIS [59]. Conceivably, prior studies of
islets underestimated the effectiveness with which glucose stimulates
cAMP production since measurements of cAMP content in whole islet
lysates do not reﬂect the true concentration of cAMP in mitochondria.
Live-cell imaging studies using cAMP reporters targeted to the mito-
chondria should resolve these issues.
If mitochondrial sAC activity is of importance to GSIS, a pharmacolog-
ical inhibitor of sAC should uncouple glucosemetabolism fromcAMPpro-
duction and insulin secretion. Unfortunately, the most commonly used
sAC inhibitor (KH7) is now recognized to exert non-speciﬁc inhibitory ef-
fects on glucose metabolism [60] and mitochondrial respiration [61].
Such non-speciﬁc effects of KH7 render it difﬁcult to interpret prior re-
ports that KH7 blocks cAMP production and insulin secretion in response
to glucose [44,62]. Established alternatives to the use of KH7 include cat-
echol ester-mediated inhibition of sAC catalytic activity [62], or siRNA-
mediated knockdownof sAC expression [62]. Still, neither of these two al-
ternative approaches allows selective targeting of mitochondrial sAC in
the absence of any effect at cytosolic sAC. The availability ofmore speciﬁc
inhibitors would be useful in order to test for a potential functional inter-
action of mitochondrial sAC and TMACs. For example, if mitochondrial
sAC activation upregulates glucose-dependent mitochondrial ATP pro-
duction, the resultant depolarization-induced Ca2+ inﬂux might have
the capacity to activate the type 8 TMAC (AC-8) that is under the control
of Ca2+/calmodulin in rodent beta cells [63–65].
Since sAC expression is not restricted to mitochondria [56], it is easy
to imagine a scenario in which glucose-stimulated mitochondrial CO2
production generates HCO3− that stimulates cytosolic sAC to activate
cAMP-dependent protein kinase A (PKA) located in the vicinity of secre-
tory granules. If so, this signaling cascademight explain prior reports that
PKA mediates the action of glucose to stimulate insulin secretion [66],
possibly by promoting the phosphorylation of Snapin [67], by increasing
the Ca2+ sensitivity of exocytosis [68], or by activating SAD-A kinase
(SAD-AK) to stimulate cytoskeletal remodeling that enables secretory
granule exocytosis during 2nd phase GSIS [69,70]. Since sAC and PKA
are both found within nuclei of cells [56,71], sAC might also mediate
stimulatory effects of glucose to elevate nuclear levels of cAMP, and to ac-
tivate beta-cell gene transcription that is PKA and CREB regulated [71].
Interestingly, sAC-stimulated cAMP production also has the capacity
to activate Rap1 GTPase in PC12 cells [72]. Rap1 is the immediate down-
stream effector of the cAMP-regulated guanine nucleotide exchange
factors Epac1 and Epac2 [73,74], and Rap1 links cAMP production to
the PKA-independent stimulation of insulin secretion [1,14,75–83].
Thus, it is remarkable that a knockout (KO) of Epac1 gene expression
leads to defective GSIS and a loss of glucoregulation in mice [84].
Furthermore, a KO of Epac2 gene expression in mice leads to a failure
of glucose to stimulate insulin secretion under pathophysiological
conditions of diet-induced insulin resistance [85,86]. Thus, there is
good reason to believe that Epac proteins mediate stimulatory effects
of glucose on insulin secretion, and that sAC might participate in this
process by raising levels of cAMP. These possibilities are testable using
newly described synthetic small molecules that selectively inhibit
Epac proteins [87–89].
To understand the potential roles of sAC and Epac2 in the control of
GSIS, it is important to note that when beta cells are stimulated with
glucose, Epac2 is recruited to the plasma membrane by activated RasGTPase [90]. This recruitment is mediated by binding of Ras to the
Ras-association (RA) domain of Epac2, and it requires that Epac2 be
activated by cAMP [90]. Remarkably, the recruitment of Epac2 to active
Ras is also Ca2+-dependent [90]. This ﬁnding is understandable if
glucose metabolism stimulates Ca2+ inﬂux that activates a Ca2+-
sensitive and Ras-speciﬁc guanine nucleotide exchange factor such as
Ras-GRF1 [91]. Using TIRF microscopy to monitor the inner surface of
the plasma membrane, Idevall-Hagren et al. ﬁnd that glucose induces
oscillations of cAMP and Ca2+ that are synchronized with Ras and
Rap1 activation, and that correlate with reversible translocation of
Epac2 to the plasma membrane [90]. Although these oscillations are
blocked by an inhibitor of TMACs [90], it is possible that glucosemetab-
olism activates mitochondrial sAC to generate cAMP and Ca2+ signals
that support this oscillatory activity. For example, if sAC-catalyzed
cAMP production in mitochondria facilitates glucose-dependent oxida-
tive phosphorylation, the resultant increase of ATP/ADP concentration
ratio will provide the metabolic signal for K-ATP channel closure and
depolarization-induced Ca2+ inﬂux. This Ca2+ signal will activate Ras-
GRF1 to sequentially activate Ras, while also acting at the AC-8 TMAC
to further stimulate cAMP production. The net effect will be a periodic
recruitment of Epac2 to the plasma membrane, and this periodicity
will be dictated by oscillations of [Ca2+]i that are initiated by oxidative
glucose metabolism under the control of sAC.
When evaluating the above-summarized beta-cell cAMP signaling
mechanisms controlling insulin secretion, it is important to note that
permissive PKA activity supports GSIS from rodent and human islets,
even in the absence of any added cAMP-elevating agent [66,92]. Such
ﬁndings indicate that it will be important in future studies to ascertain
whether the permissive PKA activity that supports GSIS is generated
by sAC and/or TMACs. Just as important, it will be of interest to deter-
mine if sAC or TMAC activity is altered in donor islets of T2DM patients.
Prior studies using rat models of T2DM indicate that islets of these rats
have a defective coupling of glucose metabolism to cAMP production
[93,94].5. Investigation of sAC activity using an insulin-secreting cell line
Ramos et al. report that a step-wise increase of glucose concentration
from 2.5 to 16 mM leads to cAMP production in rat INS-1E insulin-
secreting cells [62]. The response appears slowly (peak at 15 min) and
is measurable under conditions in which cells are treated with the cyclic
nucleotide phosphodiesterase (PDE) inhibitor IBMX. Despite interpretive
problems associated with the lack of speciﬁcity of sAC inhibitor KH7 (see
above) Ramos et al. also ﬁnd that the cAMP-elevating action of glucose is
suppressed by KH7, whereas a P-site inhibitor of TMACs (ddAdo) is inef-
fective. In contrast, the action of GLP-1 to raise levels of cAMP is unaffect-
ed by KH7 but is blocked by ddAdo. Immunoprecipitation, western blot,
and immunocytochemical analyses also demonstrate the expression of
a ca. 50 kDa isoform of sAC in these INS-1E cells. Knockdown of sAC ex-
pression using sAC-speciﬁc siRNA reduces levels of sAC protein while
also reducing the action of glucose to stimulate cAMP production [44,
62]. Interestingly, agents that interfere with depolarization-induced
Ca2+ inﬂux (diazoxide, verapamil) or that buffer intracellular Ca2+
(EGTA-AM) eliminate the action of glucose to raise levels of cAMP [62].
Collectively, these ﬁndings indicate that for INS1-E cells, the binding
of Ca2+ to a TMAC (i.e., AC-8) or sAC is of signiﬁcance to glucose-
stimulated cAMP production. However, it is not yet possible to deci-
pher which of these two adenylyl cyclases play a dominant role in
the overall process of glucose-stimulated cAMP production. Finally,
the utility of INS-1E cells for studies of this type is further empha-
sized by the ﬁnding that KH7, but not the TMAC inhibitor ddAdo, un-
couples glucose metabolism from cAMP-dependent activation of
ERK1/2 mitogen-activated protein kinases [62]. Moreover, the sAC
inhibitors KH7 and catechol estrogen block glucose-stimulated insu-
lin secretion from INS-1E cells [44].
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Using a new strain of sAC-C1mice inwhich there is a global KO of sAC
gene expression, Zippin et al. report that sAC participates in the in vivo
control of blood glucose homeostasis [44]. This ﬁnding is established by
comparing glucoregulation in homozygous sAC-C1−/− KOmice as com-
pared with heterozygous sAC-C1+/−mice containing a single wild-type
sAC allele. Thus, in an intraperitoneal (i.p.) glucose tolerance (IPGT) test
that reveals direct stimulatory effects of glucose at the endocrine pancre-
as, levels of blood glucose rise to higher levels after the administration of
glucose to sAC−/− KO mice. Furthermore, the i.p. administration of glu-
cose to sAC−/− KOmice stimulates only a small increase of plasma insu-
lin in comparison with sAC+/− mice. Such ﬁndings indicate that sAC
expression is necessary in order for glucose tolerance and insulin secre-
tion to be homeostatically regulated under conditions of i.p. glucose
administration.
Zippin et al. also report remarkable ﬁndings concerning assays of 1st
and 2ndphaseGSIS using isolated islets of sAC-C1 KOmice [44]. By com-
paring insulin secretion from islets of sAC+/+wild-typemice or sAC−/−
KOmice, Zippin et al. demonstrate that for the sAC KO, there is a reduc-
tion of both 1st and 2nd phase GSIS, asmeasuredwhen the glucose con-
centration is stepped from5mMto 30mM. Although a detailed analysis
of islet insulin content and beta-cell mass has yet to be provided, histol-
ogy demonstrates that the homozygous sAC-C1 KO mice have normal
pancreatic morphology, normal islet structure, and normal islet size
[44]. However, one important caveat to the interpretation of these stud-
ies is that the KO of sAC gene expression is not restricted to beta cells in
sAC-C1 KO mice. Therefore, it will be important to assess how
glucoregulation is altered in beta-cell speciﬁc sAC KO mice.
7. Is there a role for sAC in metabolic processes of
beta-cell compensation?
When considering future avenues of research regarding sAC, it will
be especially important to assess whether sAC participates in processes
of beta-cell compensation that serve to maintain GSIS under conditions
of metabolic stress. For example, it could be that the beta-cell cAMP
signaling “network” exhibits plasticity under conditions of metabolic
stress, and that sAC-stimulated cAMP production explains enhanced
GSIS that serves to counteract insulin resistance induced by metabolic
stress. A hint that this might be the case is provided by the study of
Song et al. inwhichmetabolic stress induced by a high fat diet (HFD) re-
veals a prominent role for Epac2 in the control of GSIS [85]. The HFD in-
duces insulin resistance, and under these conditions, mouse beta cells
undergo functional compensation to upregulate GSIS, whereas this
compensation is lost in beta cells of Epac2 KO mice [85]. Based on the
ﬁndings of Song et al., HFD-induced beta-cell compensation in mice ap-
pears to involve an increased capacity of glucose metabolism to signal
through Epac2 to increase levels of cytosolic Ca2+ [85]. Importantly,
this compensation is measureable in assays of GSIS using isolated islets,
and it occurs in the absence of an added GPCR agonist [85]. Since Epac2
activation in normal wild-type beta cells promotes Ca2+ inﬂux while
also mobilizing an intracellular source of Ca2+ [95–102], the coupling
of sAC activity to Epac2 activation and Ca2+ handling seems like a fruit-
ful area for future investigation. Potentially, sAC-C1 KO mice can be
evaluated in order to determine if processes of beta-cell compensation
important to GSIS are disrupted under conditions of the HFD. Since
cAMP-elevating agents stimulate beta-cell proliferation [103–105],
while protecting against beta-cell death [106], sAC activity might also
maintain beta-cell mass under conditions of metabolic stress.
8. Regulation of beta-cell cAMP production by GPCRs and TMACs
sAC-catalyzed cAMP production in response to glucose is
complemented by TMAC-catalyzed cAMP production that is initiat-
ed by agonist binding to G protein-coupled receptors (GPCRs). TheGPCRs that stimulate cAMP production in beta cells include members
of the Family B GPCRs that speciﬁcally bind glucagon, GLP-1, GIP, and
PACAP [34,35,107]. Traditionally, it is thought that these GPCRs mediate
the intra-islet (glucagon), hormonal (GLP-1, GIP) and neural (PACAP)
stimulation of insulin secretion. However, recent ﬁndings indicate that
GLP-1 released from intestinal L-cells also activates vagal–vagal reﬂexes
that stimulate insulin secretion [35,108]. For the treatment of T2DM, syn-
thetic GLP-1 receptor agonists exist, and they include exenatide and
liraglutide [35].
Signal transduction crosstalk of sAC and TMACs might exist in beta
cells because sAC-catalyzed cAMPproduction inmitochondria is predict-
ed to enhance the action of glucose to promote depolarization-induced
Ca2+ inﬂux, thereby allowing Ca2+ to directly stimulate TMAC activity.
Multiple isoforms of TMACs are expressed in beta cells [63], and in this
regard AC-8 is especially important for rodent beta cells due to the fact
that it serves as a molecular coincidence detector for the cAMP-
dependent control of GSIS [64,65]. Coincidence detection at AC-8 occurs
because the activity of AC-8 is stimulated by heterotrimeric Gs proteins
and also by Ca2+/CaM that binds directly to AC-8 [109,110]. For example,
we propose that binding of GLP-1 to its GPCR stimulates AC-8, and that
this effect is reinforced by glucose metabolism that is under the control
of sAC and that elevates levels of Ca2+ in order to further stimulate AC-
8. Synergistic activation of AC-8 is achieved when GLP-1 is paired with
glucose, and under these conditions oscillations of cAMP and Ca2+ are
generated so that GSIS is powerfully stimulated [111–116].
An additional noteworthy ﬁnding is the recent report of Hodson et al.
that human islet GSIS is conditional on the expression of the TMAC iso-
form 5 (AC-5) in beta cells [117]. In studies of human islets subjected
to an shRNA-mediated knockdown of AC-5, it is possible to demonstrate
that reduced AC-5 expression leads to amodest but signiﬁcant reduction
of GSIS under conditions in which the glucose concentration is stepped
from 3 to 11mM. In contrast, a knockdown of AC-5 does not alter the ac-
tion ofGLP-1 to stimulate insulin secretion under conditions inwhich the
glucose concentration is ﬁxed at 11 mM. By imaging the ﬂuorescent
cAMP reporter Epac2-camps, or the ﬂuorescent Ca2+ reporter ﬂuo-2, in
single human islets or single human beta cells, it is also possible to dem-
onstrate that glucose is a less effective stimulus for cAMP production and
Ca2+ inﬂux in islets subjected to the knockdown of AC-5. Such ﬁndings
are surprising in view of the fact that AC-5 was previously considered
to be an adenylyl cyclase that is inhibited by Ca2+. However, Hodson
et al. point out that AC-5 is inhibited by concentrations of Ca2+ that are
in excess of that normally found in the cytosol [117]. Taken as a whole,
such ﬁndings concerning AC-5 are consistent with the prior ﬁnding of
Chepurny et al. demonstrating a role for permissive PKA activity in sup-
port of GSIS [92], aswell as the ﬁndings of Hatakeyama, Takahashi, Kasai,
and co-workerswho propose that beta-cell glucosemetabolism is tightly
linked to TMAC-stimulated cAMP production [66,118,119]. One particu-
larly interesting outgrowth of this line of investigation is the apparent
role of AC-5 as a signal transducer linking human beta-cell glucose
metabolism to depolarization-induced Ca2+ inﬂux [117]. Although it
remains to be demonstrated, cAMPgenerated in response to glucoseme-
tabolism might be linked to Epac2 activation with consequent K-ATP
channel closure that generates beta-cell depolarization [95,96].
9. Conclusion
Over forty years have elapsed since the ﬁrst reports documenting an
ability of glucose to raise levels of cAMP in the islets of Langerhans
[120–131]. With time, these studies were discounted due to the rela-
tively small change of cAMP concentration induced by glucose. Since
such prior studies used biochemical assays to detect levels of cAMP in
whole islets, we propose that these studies need to be reinterpreted be-
cause the methods that were used cannot detect compartmentalized
cAMP production that is potentially sAC-mediated. Importantly, earlier
studies found that the time course of 1st phase GSIS matched that of
the glucose-stimulated increase of cAMP concentration in whole islets
2598 G.G. Holz et al. / Biochimica et Biophysica Acta 1842 (2014) 2593–2600[121,126,127]. In retrospect, this temporal coincidence is understand-
able if 1st phase GSIS results from exocytosis that is at least in part
cAMP-stimulated [14]. In this regard, we wish to emphasize that
cAMP is not the only stimulus for GSIS, but that additional metabolic
coupling factors derived from glucose metabolism also participate.
However, since genetically-encoded cAMP biosensors are able to de-
tect glucose-stimulated changes of cAMP concentration in single
beta-cells and whole islets [90,112,113,132,133], there exists a new
appreciation for actions of glucose to stimulate insulin secretion in
a cAMP-mediated manner [134]. In fact, a capacity of cAMP to direct-
ly stimulate beta-cell exocytosis is convincingly documented in the
report of Ammala et al. published in 1993 [135], at which time the
functional signiﬁcance of sAC was not yet appreciated. However,
since the cloning of sAC from a rat testis cDNA library in the late
1990s [136], the signiﬁcance of sAC to cAMP signaling in many cell
types is increasingly apparent. With the availability of sAC KO mice
in which there is defective glucoregulation accompanied by reduced
GSIS [44], it is anticipated that the full signiﬁcance of sAC to beta-cell
biology, and possibly T2DM, will become readily apparent.
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